Wall Street brokerages expect Merit Medical Systems, Inc. (NASDAQ:MMSI) to post $230.12 million in sales for the current quarter, according to Zacks Investment Research. Five analysts have provided estimates for Merit Medical Systems’ earnings, with estimates ranging from $225.23 million to $235.83 million. Merit Medical Systems posted sales of $190.90 million in the same quarter last year, which would indicate a positive year over year growth rate of 20.5%. The company is expected to report its next earnings report on Wednesday, February 27th.

According to Zacks, analysts expect that Merit Medical Systems will report full year sales of $879.63 million for the current year, with estimates ranging from $874.73 million to $885.33 million. For the next financial year, analysts expect that the firm will report sales of $1.01 billion, with estimates ranging from $934.00 million to $1.05 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover Merit Medical Systems.

Several research analysts recently commented on the company. Zacks Investment Research cut Merit Medical Systems from a “hold” rating to a “sell” rating in a research report on Wednesday, October 24th. ValuEngine upgraded Merit Medical Systems from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, October 24th. Canaccord Genuity raised their target price on Merit Medical Systems from $70.00 to $72.00 and gave the company a “buy” rating in a report on Friday, October 26th. Needham & Company LLC reissued a “buy” rating and set a $73.00 price objective on shares of Merit Medical Systems in a report on Monday, December 17th. Finally, BidaskClub lowered Merit Medical Systems from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 5th. One investment analyst has rated the stock with a sell rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. Merit Medical Systems currently has a consensus rating of “Buy” and a consensus price target of $67.60.

Shares of Merit Medical Systems stock traded up $1.78 during trading hours on Friday, hitting $57.59. The company’s stock had a trading volume of 4,641 shares, compared to its average volume of 261,386. The company has a debt-to-equity ratio of 0.20, a current ratio of 2.77 and a quick ratio of 1.47. The company has a market capitalization of $3.12 billion, a P/E ratio of 44.70, a price-to-earnings-growth ratio of 2.18 and a beta of 1.12. Merit Medical Systems has a 12 month low of $41.55 and a 12 month high of $66.34.

In other Merit Medical Systems news, EVP Justin J. Lampropoulos sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, November 16th. The shares were sold at an average price of $61.01, for a total transaction of $1,220,200.00. Following the transaction, the executive vice president now owns 20,000 shares in the company, valued at approximately $1,220,200. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Nolan E. Karras sold 2,000 shares of the stock in a transaction on Thursday, November 29th. The stock was sold at an average price of $61.28, for a total transaction of $122,560.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 26,743 shares of company stock worth $1,633,506. Insiders own 5.16% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of MMSI. Bank of New York Mellon Corp increased its position in shares of Merit Medical Systems by 5.9% during the fourth quarter. Bank of New York Mellon Corp now owns 875,501 shares of the medical instruments supplier’s stock valued at $48,862,000 after acquiring an additional 48,526 shares during the last quarter. Lisanti Capital Growth LLC lifted its stake in Merit Medical Systems by 91.5% in the fourth quarter. Lisanti Capital Growth LLC now owns 93,620 shares of the medical instruments supplier’s stock worth $5,225,000 after acquiring an additional 44,720 shares during the last quarter. New York State Common Retirement Fund lifted its position in shares of Merit Medical Systems by 0.8% during the 4th quarter. New York State Common Retirement Fund now owns 88,382 shares of the medical instruments supplier’s stock worth $4,933,000 after buying an additional 707 shares during the last quarter. Piedmont Investment Advisors Inc. increased its holdings in shares of Merit Medical Systems by 3.4% in the 4th quarter. Piedmont Investment Advisors Inc. now owns 13,022 shares of the medical instruments supplier’s stock valued at $727,000 after acquiring an additional 434 shares during the period. Finally, Oregon Public Employees Retirement Fund acquired a new position in shares of Merit Medical Systems in the 4th quarter valued at $1,164,000. Institutional investors and hedge funds own 98.53% of the company’s stock.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc engages in the manufacture and market of proprietary disposable medical devices. It operates through Cardiovascular and Endoscopy segments. The Cardiovascular segment consists of peripheral intervention, cardiac intervention, interventional oncology and spine, and cardiovascular and critical care product groups.

Read More: What is a stock buyback?

Get a free copy of the Zacks research report on Merit Medical Systems (MMSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Merit Medical Systems (NASDAQ:MMSI)

Receive News & Ratings for Merit Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merit Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.